PNPLA3 and metabolic dysfunction-associated steatotic liver disease: In addition, NAFLD patients with PNPLA3 mutation showed a lower CV risk compared to “metabolic” NAFLD patients, questioning as to whether NAFLD represents an independent CV risk factor.